Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1–positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States
2017 ◽
Vol 23
(6)
◽
pp. 653-664
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2021 ◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. e17551-e17551
◽